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CD271 determines migratory 
properties of melanoma cells
Josefine Radke1,2,5,6, Florian Roßner4,5 & Torben Redmer1,3,4,5
Melanoma cell expression of the nerve growth factor receptor CD271 is associated with stem-like 
properties. However, the contributing role of the receptor in melanoma cell migration is elusive. Here, 
we explored extracranial (skin, soft tissue, lymph node and liver, n = 13) and matched brain metastases 
(BM, n = 12) and observed a heterogeneous distribution of phenotypically distinct subsets of CD271+ 
cells. In addition, we observed that CD271 expression gradually rises along with melanoma progression 
and metastasis by exploration of publicly available expression data of nevi, primary melanoma 
(n = 31) and melanoma metastases (n = 54). Furthermore, we observed highest levels of CD271 in BM. 
Sub-clustering identified 99 genes differentially expressed among CD271high and CD271low (p < 0.05) 
BM-subgroups. Comparative analysis of subsets revealed increased ( ≥ 1.5fold, log2) expression of 
migration-associated genes and enrichment of CD271-responsible genes involved in DNA-repair and 
stemness. Live cell-imaging based scratch-wound assays of melanoma cells with stable knock-down of 
CD271 revealed a significantly reduced cell migration (3.9fold, p = 1.2E-04) and a reduced expression 
of FGF13, CSPG4, HMGA2 and AKT3 major candidate regulatory genes of melanoma cell migration. 
In summary, we provide new insights in melanoma cell migration and suggest that CD271 serves as a 
candidate regulator, sufficient to determine cellular properties of melanoma brain metastatic cells.
Distant metastasis is still the major obstacle to overcome in melanoma therapy, associated with poor prognosis 
and a ten-year survival rate of patients with distant metastases (stage IV) <10%1. Metastatic dissemination of 
primary tumors is an early event2 and the majority of patients exhibit regional or distant metastases by the time of 
diagnosis. Melanoma cells feature a high migratory phenotype3 facilitating the colonization of distant organs e.g. 
lung, liver, heart, peritoneum, small intestine, spleen and brain4. Despite this broad spectrum of possibly involved 
organs, brain metastases are very common, observed in 20–40% of melanoma patients. In addition, brain metas-
tases are actually found post mortem in more than 75% of melanoma patients5. Moreover, multiple brain metas-
tases (>5 intracerebral metastatic lesions) are observed in 5% of melanoma patients6 and may derive either from 
one founder clone or represent independent clones of different metastatic melanoma cells. Overall, the emer-
gence of brain metastases is associated with poor prognosis due to limited therapeutic options. Stereotactic or 
whole-brain radiotherapy in combination with chemotherapy or immune-checkpoint inhibitors7 has recently 
gained increasing attention as meaningful therapeutic option for melanoma patients with brain metastases.
Migration and invasion of tumor cells are essential steps in the metastasis sequence8. Recently, the expression 
of nerve growth factor receptor CD271 was associated with increased incidence of melanoma brain metastases9 
as well as metastases in lung, liver and kidney10. Furthermore, the BRAFV600E mutation intrinsically confers a high 
migratory phenotype to melanoma cells11, blocked by the potent RAF-kinase inhibitor vemurafenib. Contrary, 
patients under vemurafenib therapy show a higher incidence for brain metastases as compared with patients who 
did not receive vemurafenib12. In addition, acquisition of melanoma cell resistance to vemurafenib as well as a 
higher tendency of brain metastasis was associated with expression of CD27113, 14. Hence, CD271 expression may 
prime melanoma cells intrinsically for extensive migration, metastasis and brain tropism. Apart from melanoma, 
other tumor entities bearing CD271+ cells15 also show comparable prevalence for brain metastasis, e.g. breast 
cancer (15–30%, reviewed in ref. 16). In glioblastoma, CD271+ cells represent a cellular sub-set highly capable of 
migrating and infiltrating the brain parenchyma17. However, it remains elusive whether CD271+ cells present a 
cell subpopulation prone to metastasize to the brain.
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Here we explored the presence and distribution of CD271 expressing cells in primary melanoma as well as 
in extracranial, solitary and multiple brain metastases and elucidated the potential role of CD271 in melanoma 
brain tropism.
Results
Expression of CD271 discriminates melanoma progression stages and defines subsets of mel-
anoma metastases. Melanoma cells facilitate a high migratory phenotype18 capable of radial or vertical 
migration, reviewed in ref. 19. To explore whether CD271+ melanoma cells are prone to metastasize to the brain, 
we analyzed matched pairs of primary tumors (n = 2), extracranial (n = 13) and brain metastasis (n = 12) as well 
as unmatched brain (n = 7) and extracranial (n = 1) metastases of melanoma for expression of CD271, irrespec-
tive of the BRAF mutation status and therapeutic interventions (Supplementary information, SI; Table S1). We 
observed a median CD271 expression of 32% (range 0.5–100%) in extracranial and 11.9% (range 0.5–100%) in 
brain metastases. Hence, expression of CD271 was not significantly increased in either of these groups (Fig. 1A,B) 
and reflected strong inter-sample variations among melanoma metastases and primary tumors (Fig. 1B, left 
panel, p = 0.081; SI, Figures S1 and S2A,B). Highest CD271 expression (90%) was observed in a desmoplastic 
neurotrophic melanoma (DNM) and corresponding skin (n = 2) and brain metastases (n = 1), (Fig. 1A and SI, 
Figure S3A; Patient 1). In superficial spreading melanoma (SSM), we observed randomly distributed CD271+ 
cells within the tumor bulk or expression of CD271 at tumor edges and a wide-spread distribution in a soft 
tissue (ST) metastasis (Fig. 1A, Patients 2, 3). In healthy skin, CD271 expression was found in proliferating and 
non-proliferating (Ki67+/Ki67−) cells of the basal layer, and MART1+ or MITF+ melanocytes (SI, Figure S4A). 
Exploration of lymph node metastases not only revealed the presence of CD271+ tumor cells but also a prominent 
expression of CD271 in adjacent lymph follicles (LN) (SI, Figure S4B).
In a primary tumor of uveal melanoma (n = 1) we observed CD271 expression in the choroid cells as well as 
in spindle-shaped (Spin) but not epithelioid-appearing (Epi) tumor cells (SI, Figure S5A). In the associated liver 
and brain metastasis, we observed expression of CD271 in tumor cells (T) as well as in interstitial or stromal and 
vessel-adjacent cells (SI, Figures S5B,C).
Further, we explored publicly available expression data (GSE755320) of melanoma metastases (MET, n = 34), 
primary melanoma (PM, n = 14), melanoma in situ (MIS, n = 2), melanocytes (Mel, n = 1), basal cell carcinoma 
(BCC, n = 15), squamous cell carcinoma (SCC, n = 11) and normal skin (NS, n = 4). We observed highest CD271 
expression in MET, as compared to PM (p = 0.032) which in turn show higher CD271 levels as compared to 
BCC (p = 0.034) and SCC (not significant, NS) (Fig. 1B, right panel). In addition, we observed a high variance 
of CD271 expression levels among primary melanoma subtypes: Acral, SSM, Nodular, Desmoplastic, LMM and 
spindle cell melanoma (GSE1560521), (SI, Figure S6A). We next asked for levels of CD271 expression along stages 
of melanoma evolution and progression (GSE4651722). We observed that expression of CD271 increased with 
melanoma progression and attained significantly (p = 0.018) highest levels in MET (n = 54) as compared to PM, 
n = 31 (Fig. 2A, left panel), which is in line with a previous observation23. Together, our findings are underpinned 
by public data and demonstrate the existence of subsets of melanoma metastases with high expression of CD271. 
This was further evaluated with expression data of metastases of different metastatic sites (GSE50493). We 
observed a subset of BM (n = 5 of 29, 17.2%) with strong CD271 expression (Fig. 2A, right panel). Next, we asked 
whether a high level of CD271 indeed determines the character of these CD271high tumors. A comparative analy-
sis of expression data of CD271high BM (BM-CD271high) or low (CD271low) CD271 expression led to identification 
of 2834 differentially regulated genes (p ≤ 0.05). Among them we identified 62 genes with increased ( ≥ 1.5fold, 
log2; p ≤ 0.05) and 37 genes with decreased ( ≤ 1.5fold, log2; p ≤ 0.05) expression in the CD271high subset as 
compared to CD271low tumors (Fig. 2B). Tumors of the CD271high subset showed a ~5fold higher CD271 expres-
sion (p = 0.002) as compared to CD271low brain tumors (n = 13), (SI, Figure S6B-C). Among the top regulated 
genes we found those associated with cell migration e.g. NRCAM24 (neural cell adhesion molecule), TWIST125 or 
LOX26 (lysyl oxidase) (Fig. 2B). In addition, gene-set enrichment analysis (GSEA) of both subsets of brain tumors 
demonstrated that CD271 expression is associated with enrichment of CD271-responsible genes27 (NES = 2.20), 
(Fig. 2C). Next, we asked for CD271-responsible genes potentially up-regulated in the CD271high subgroups of 
brain metastases (BM) in independent data sets (GSE50493, GSE44660). We found CD271-responsible genes 
up-regulated in either of the two groups of CD271high BM (Fig. 2C, right panel). In addition, we found commonly 
regulated genes associated with metastasis; TUBB2B28 and PMEPA129, besides NGFR. Further exploration of 
genes differentially regulated among the CD271high and CD271low BM subsets revealed commonly up-regulated 
(n = 10) and down-regulated (n = 5) genes. Among genes with significantly increased expression in the CD271high 
subsets were mediators of tumor cell migration e.g. AXL30 and members of the lysyl-oxidase family LOX26 and 
LOXL231 as well as the less characterized SERTAD4 (SERTA Domain-Containing Protein 4), (SI, Figure S6D-E). 
In addition, we found increased expression of the receptor-tyrosine kinase c-MET in the CD271low groups only 
(SI, Figure S6E). Additional GSEA of CD271high and CD271low subsets identified a global enrichment of genes 
associated with DNA-repair (NES = 2.05), a neural-crest cell stem-like (NCSC) state (NES = 1.89) or formation of 
cell projections, a prerequisite for cell migration and a brain metastatic phenotype in the subset of CD271high BM 
(GSE50493), (SI, Figure S7A and S7B, left panel). Furthermore, we observed enrichment of genes associated with 
a EMT (epithelial to mesenchymal transition) cellular phenotype and CD271-dependent response in CD271high 
BM of GSE44660 (SI, Figure S7B). Together these data suggest that CD271 serves as a subclassifier of melanoma 
brain metastases.
Tumor cell metastasis relies on the formation of focal adhesive contacts and the migratory capacity8. We pre-
viously observed a high migratory phenotype of A375 melanoma cells which was strongly enhanced (~15fold, 
p = 9.9E-8) by over expression of CD271 (A375CD271/NGFR cells)27, (Fig. 2D, left panel). We observed that genes 
associated with focal adhesion as well as lamellopodia structures are strongly enriched in A375CD271/NGFR cells 
(Fig. 2D, right panel and SI, Figure S7C) as compared to A375GFP cells. In addition, we followed migration of 
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Figure 1. CD271 expressing cells are phenotypically distinct in extracranial and brain metastases. (A) 
Immunohistochemistry of three representative matched pairs of melanoma extracranial (EM) and 
corresponding brain metastases (BM, Patient 1 and 2), or soft tissue metastases (MET) and corresponding 
BM (Patient 3) for presence of CD271 and MART1 or hematoxylin/eosin (H&E). Scale bars indicate 50 µm. 
(B) Left panel: Box-plots show the number of CD271+ cells (%) of BM (n = 19), primary tumors (PM; n = 2) 
and EM (n = 14) as determined by counting of 50 visual fields at 200x magnification, p = 0.081. Right panel: 
Visualization of CD271/NGFR expression levels (log2) of skin cancer subtypes (GSE7553) including MET 
(n = 34), PM (n = 14), melanoma in-situ (MIS; n = 2), melanocytes (Mel.; n = 1), basal cell carcinoma (BCC; 
n = 15), squamous cell carcinoma (SCC; n = 11) and normal skin (NS). Significant difference in expression 
levels among MET/PM (p = 0.032) and PM/BCC (p = 0.034) is shown. Black filled circles indicate number of 
samples. If not stated otherwise, p-values were calculated by Wilcoxon rank-sum test.
www.nature.com/scientificreports/
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Figure 2. CD271 expression characterizes melanoma metastases. (A) Left panel: Visualization of CD271/
NGFR expression levels (log2) at different melanoma progression stages (GSE46517): MET (n = 54), PM 
(n = 31), melanocytic nevus (Nevus; n = 9), NS (n = 7) and melanocytes (Mel.; n = 1). Right panel: CD271/
NGFR expression levels (log2) of brain metastases (Brain; n = 29, GSE50493) as well as extracranial metastases, 
lymph node (LN; n = 12), soft tissue (ST; n = 10), small intestine (S. int.; n = 4), lung (Lung; n = 6), Bowel 
(n = 1), Spleen (n = 4), Adrenal (n = 1), Bone (n = 3), Liver (n = 2). (B) Supervised clustering of brain 
metastases with high expression of CD271/NGFR (red, patients 15, 37, 42, 51 and 55) and very low expression 
(green, n = 13) of 99 genes, among them 62 genes with increased (≥1.5fold, log2; p < 0.05) and 37 genes 
with decreased (≤1.5fold, log2; p < 0.05) expression. (C) Left and right panel: Gene-set enrichment analysis 
(GSEA) of CD271high (BM-CD271high) and CD271low (BM-CD271low) brain metastases (study GSE50493) shows 
enrichment of CD271-responsive genes (n = 156; NES = normalized enrichment score; FDR = false discovery 
rate). Venn-diagram depicts the number of CD271-responsible genes, distinctly or commonly up-regulated in 
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A375GFP cells in mouse brain slice cultures by sequential confocal imaging to exemplify cell migration in a 
three-dimensional system (Movie files S1-S2). A375GFP cells showed proliferation within the slice as monitored 
by immunofluorescence microscopy (SI, Figure S8A, upper panels) and the tracking of A375GFP cells revealed 
their extensive migratory capacity (Fig. 2E, left panels and SI, Figure S9A-B) and showed the presence and dis-
tribution of migrating CD271+ cells. We tracked migration of A375GFP cells with endogenous CD271 expression 
as soon as 48 hours post injection, regarding our previous in vitro data27. Although the quantification of cells 
migrating within slices is difficult, we attempted to determine the number of cells capable of long distance migra-
tion. We measured the distance of the lower edge of the initial tumor to the most distantly migrated cells and 
observed that ~0.2–0.4% of cells reached a distance of 267–534 µm, among them were CD271+ cells (Fig. 2E; 
SI, Figure S9A). However, to ascertain whether a increased expression of CD271 is favorable for melanoma cell 
migration, A375CD271/NGFR cells which show a high constitutive and stable cell surface expression of CD271 (SI, 
Figure S7C, left panels) not affected by phenotype switching processes, were injected in parallel to control cells 
(A375GFP). Tracking of A375CD271/NGFR cells demonstrated that CD271+ cells are indeed capable of intracerebral 
migration (Fig. 2E, right panels; SI, S10A-B and Movie file S3) and proliferation (SI, Figure S8A, lower panels) fol-
lowing adaption to environmental cues of the brain tissue. In line is the finding of migrating/infiltrating CD271+ 
melanoma cells in melanoma brain metastases (SI, Figure S8B, Patient 4).
CD271 knock-down impairs melanoma cell migration. To further unravel the role of CD271 in mel-
anoma cell migration we explored the migratory capacity of a patient tumor-derived cell strain32 following stable 
shRNA mediated knock-down of CD271. The efficient knock-down of CD271 with a validated shRNA (sh#3) 
(Fig. 3A, left panels) induced a strong change in morphology, without effecting the overall number of Ki67+ cells 
but decreased the number of BrdU+ cells (59.7 ± 8.5%, shCtl. vs. 34.3 ± 15.9%, shCD271/sh#3; p = 0.077, ttest), 
(Fig. 3A, right panels and SI, Figures S11A-B), therefore impaired proliferation. Next, we ascertained whether 
cell migration was affected by loss of CD271 expression in a live cell-imaging scratch-wound assay. Tracking 
migration of CD271 knock-down cells by imaging of the scratch wound every 3 hours (72 hours in total) revealed 
a strong decrease (1.3fold, p = 6.6E-03/3.9fold, p = 1.2E-04 or 9.8fold, p = 3.1E-05 at 24/48 or 72 hours) in the 
efficacy of wound closure as early as 24h, as compared to control (shCtl.) or GFP expressing cells (Fig. 3B, left 
panel and Movie files S4-S6). Confocal microscopy of mouse brain slices 5 days post injection of 5 000 cells of 
each (shCD271, sh#4 and control, shCtl.) revealed widespread migration of CD271+ control cells, exhibiting both 
radially and vertically migration (SI, Figure S12A and Movie file S6). In contrast, the knock-down cells, which we 
monitored via GFP expression showed no or only limited proliferation and migration (SI, Figures S12B-C and 
Movie file S8), underpinning the in vitro findings.
We next asked for the CD271-responsible regulation of factors potentially involved in cell migration like 
those associated with formation of cell projections. To this end, we explored our expression data sets of mela-
noma cells with knock-down (GSE52456) or over expression (GSE78155) of CD271 by GSEA and observed a 
depletion or enrichment of genes associated with formation of cell projections (Fig. 3C). The integrative analysis 
of both gene sets revealed a subset of directly CD271-responding genes (n = 20), known to be involved in cell 
migration or metastasis e.g. fibroblast growth factor 13 (FGF13)33, chondroitin sulfate proteoglycan 4 (CSPG4)34 
(Fig. 3D). In addition, our screen identified other potential mediators of melanoma cell migration e.g. the high 
mobility group AT-hook 2 (HMGA2)35 transcription factor or AKT336. We verified that expression of CD271 
is crucial to maintain the levels of all four genes in melanoma cells stably expressing CD271-targeting shRNAs 
(sh#3/sh#4). qPCR of CD271 knock-down cells showed decreased levels of CSPG4 (p = 8.3E-04/8.1E-05), FGF13 
(p = 2.1E-03/2.2E-04), HMGA2 (p = 1.8E-02/1.4E-04) and AKT3 (p = 6.5E-04/4.9E-06), (Fig. 3E, left panel). We 
further confirmed the loss of CSPG4, FGF13 and HMGA2 by immunofluorescence microscopy (Fig. 3E, right 
panel). Next, we ascertained the potential significance of these factors in melanoma migration and metasta-
sis. To this end, we explored publicly available expression data of primary melanoma and extracranial metas-
tases (GSE46517, GSE7553, GSE8401) for levels of HMGA2. We observed that HMGA2 was predominantly 
expressed in melanoma metastases with a significant difference in two out of three studies (p = 3.6E-06, p = 0.301 
and p = 2.4E-05), (SI, Figures S13A, S14B). Since we observed a clear down-regulation of HMGA2 in CD271 
knock-down cells, we asked for genes involved in melanoma migration and metastasis supposedly driven by a 
CD271/HMGA2 axis. We initially identified 1337 (FClog2 ≤ 0.5, p ≤ 0.05) potential HMGA2-targets by exploration 
of expression profiling data of the breast cancer cell line MDA-MB-231 with HMGA2 knock-down (GSE4374137). 
We then employed expression data of our previous study (GSE52456). The integrative analysis of both sets of 
targets identified 130 genes, commonly down-regulated upon knock-down of CD271 or HMGA2 (SI, Table S3). 
Among these potential CD271/HMGA2 targets were migration and metastasis-associated genes e.g. SEMA3A, 
ST3GAL138, LOX26 and PDLIM139. Further analyses demonstrated a significantly increased level of SEMA3A and 
ST3GAL1 or decreased level of PDLIM1 in MET (SI, Figure S13B, S14A-B). Next, we ascertained the dependence 
CD271high brain metastases in two independent studies (GSE50493, GSE44660; FClog2 ≥ 1.1, p ≤ 0.05). (D) Left 
panel: Representation of the migratory capacity of A375GFP and A375CD271/NGFR cells indicated by the wound 
width [µm], 24 hours after wounding. Right panel: Enrichment of genes involved in focal adhesion formation 
(Broad institute’s MSigDB) in A375CD271/NGFR cells as determined by GSEA (E) Confocal microscopy-based 
serial imaging of mouse brain slices, 48 h after injection of 10 000 A375GFP or A375CD271/NGFR cells. Left panels: 
GFP expression of image sections, Z0/0, Z7/14, Z14/14 (inset) as well as CD271 expression (red) for Z14/14 
of slices injected with A375GFP are shown. Right panels: image sections Z0/7and Z7/7 of slices injected with 
A375CD271/NGFR are shown. Areas depicting migrating CD271+ cells are magnified. DAPI served as nuclear stain, 
scale bars indicate 50 µm. White dotted lines indicate initial tumor borders/non-migrated cells.
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Figure 3. CD271 controls expression of mediators of cell migration. (A) Left panels: Absence of CD271 
in melanoma cells (T20/02) stably transfected with a CD271-targeting shRNA (shCD271/sh#3) but high 
expression in control cells (shCtl.) as determined by immunofluorescence and a directly labeled (PE, red) 
CD271 antibody. Right panels: A changed morphology of CD271 knock-down cells is indicated by phalloidin 
(red) and bright field images (PH), as well as a decreased number of BrdU+ (red) but not Ki67+ (green) cells as 
compared to shCtl. cells. (B) Left panel: Live cell-imaging based scratch-wound assay of cells described in (A) 
at 0, 24, 48 and 72 hours after wounding. Initially, 30 000 cells/well (96-well plate) were seeded, reproducible 
wounds were scratched using the wound maker tool (Essen bioscience). Scale bars indicate 200 µm, the initial 
wound is indicated by white dotted lines. Right panel: Quantification of the scratch-wound assay, the wound 
width [µm] was determined every 3 hours. Shown are mean values ± sdv of n = 8 replicates, p = 3.1E-05 (shCtl.1 
vs. sh#3) or 9.6E-07 (shCtl.2 vs. sh#3), ttest. (C) Left and right panel: CD271-responsible regulation of genes 
associated with formation of cell projections as determined by GSEA of T20/02 cells engineered for stable 
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of HMGA2, PDLIM1 and SEMA3A expression of CD271. We ranked MET regarding their CD271 levels and 
observed a CD271-dependency of SEMA3A but not HMGA2 or PDLIM1 expression in CD271high metastases (SI, 
Figure S14A-B). Further, we evaluated CSPG4 and FGF13 expression in MET and observed a non-significant or 
only partially significant difference in expression of CSPG4 or FGF13 among primary and metastatic melanoma 
(SI, Figures S13D, left panels; S13E and S14A), respectively. Although CSPG4 and CD271 are co-expressed in a 
subset of melanoma cells of MeWoPar (parental MeWo) and T20/02 (SI, Figure S13D, right panels), their role in 
cell migration and metastasis might be different.
Activation of the PI3K/AKT pathway has been recognized as a potent driver of melanoma progression and 
metastasis, including metastasis to the brain36, 40, 41. We asked whether the decrease of AKT3 expression in CD271 
knock-down cells affected the overall activation of this pathway. We observed a reduced level of activated AKT, 
phosphorylated at S473 (p-AKTS473) in CD271 knock-down cells but no changes in the levels of activated extra-
cellular signal-regulated kinases 1/2 (p-ERK1/2), (SI, Figure S13F, left panels). In addition, sorting of melanoma 
cells for CD271 demonstrated a predominance of activated PI3K/AKT signaling in CD271+ cells (SI, Figure S13F, 
right panels).
Together, these data suggest that CD271 may control migration and metastasis mechanisms supposedly via a 
network of mediators e.g. HMGA2 or FGF13 or AKT- signaling (SI, Figure S14C).
Inspection of multiple brain metastases reveal phenotypical concordance. The mechanisms 
underlying melanoma metastasis to the brain are still poorly understood. Therefore the identification of key 
players determining brain metastases is mandatory.
In principle, several hypothetical scenarios for the seeding of primary tumors (PT) or extracranial metastases 
(EM) are plausible. Multiple seeding of CD271high or CD271low tumor cells should lead to intratumor heterogene-
ity of brain metastases (Fig. 4A, left scheme). The single seeding of PT/EM and establishment of a founder clone, 
derived from brain metastatic cells would increase the likelihood for the formation of multiple brain metastases 
with comparable phenotypes. The latter is given by seeding of the founder clone (Fig. 4A, center scheme). In 
another scenario, seeding of a founder clone and PT/EM again would lead to increased phenotypic heterogeneity 
among brain metastases (Fig. 4A, right scheme). Related to these potential mechanisms, we asked for the occur-
rence and dissemination of CD271+ cells among autopsied tumor samples of patients with multiple (n ≥ 2) brain 
metastases. Again, we found strong inter-patient heterogeneity of CD271 expression. Nevertheless, multiple brain 
metastases derived from one patient (T1) revealed a homogeneous distribution of CD271+ cells accompanied 
by a high expression of S100 but absence of MART1 (Fig. 4B and SI, Figure S15A). The relationship of CD271, 
S100 and MART1 was found in additional brain metastases of patient T2 (SI, Figure S15B). CD271 expression of 
tumors was distinct from neurons residing in the brain parenchyma. In addition, we observed infiltration of the 
adjacent brain parenchyma by migrating CD271+ cells (Fig. 4C), clearly suggesting that CD271+ cells are capable 
of seeding within the brain and potentially associated with the formation of multiple brain metastases. Next, we 
ascertained the presence of CD271+ cells in brain micrometastases of autopsied brain tissue samples (cerebellum, 
hippocampus, cortex) of a patient with additional metastases in liver, lung and spleen (Patient T3; SI, Table S2). 
We found CD271+ cells albeit with low frequency, in four out of six micrometastases of different regions, (Fig. 4D 
and SI, Figure S16A).
The dissemination of melanoma cells via the blood stream is not the only mechanism of distant metastasis. 
Besides this passive process, melanoma cells actively migrate along vessels by vessel co-option42. In brain metas-
tases, we observed CD271+ cells adjacent to blood vessels as well as a clear, distinct staining of endothelial (CD31) 
and melanoma cells (CD271), (SI, Figure S16B). In addition, we very rarely observed CD271+ supposedly mel-
anoma cells in a blood vessel (SI, Figure S16C) as well as a potential blood-vessel directed migration of CD271+ 
cells (SI, Figure S16D).
Expression of the microphthalmia-associated transcription factor (MITF) is down-regulated 
in CD271high brain metastases. Low expression of MITF has been associated with a more aggressive, 
stem like and tumor-initiating phenotype of melanoma cells43, 44. We explored solitary (Patient 1) and multiple 
(Patient T1) melanoma BM with a CD271high phenotype for expression of MITF by co-immunohistochemical 
staining. Basically, we observed a mutually exclusive expression pattern of CD271 and MITF and in addition a 
transition-state where expression of both markers was not clearly separated (Fig. 5A; Patient 1, BM). In multiple 
BM, MITF expression was not detected in areas strongly positive for CD271 (cortical metastasis). However, MITF 
was expressed in CD271 negative tumor areas adjacent to normal tissue in the cerebellar metastasis (Fig. 5A; 
Patient T1). Next, we determined the proportion of proliferating, Ki67+ cells in BM (n = 5) and EM (n = 6) and 
observed no correlation between CD271 expression and the proliferative state. Moreover, the non-proliferating 
CD271 expressing cells most likely constitute the stem-like subset, responsible for tumor progression as 
down-regulation (T20/02k.d.) or over expression (T20/02CD271/NGFR) of CD271. (D) Representation of genes 
found either up-regulated or down-regulated by knock-down or over expression, respectively. A common 
set of 20 genes followed a CD271-responsible regulation among them FGF13 and CSPG4. (E) Left panel: 
Determination of expression levels of potential migration-associated genes CSPG4, FGF13, HMGA2 and AKT3 
by qPCR of T20/02 cells either stably transfected with control shRNA (shCtl) or effective CD271-targeting 
shRNAs (sh#3, sh#4; sh#2, not effective). Relative expression levels are shown as mean values ± sdv of biological 
triplicates, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05, ttest. Right panel: Immunofluorescence microscopy for levels of 
CSPG4, FGF13 and HMGA2 in shCtl. and CD271 knock-down cells (sh#3). DAPI served as nuclear stain, scale 
bars indicate 50 µm.
www.nature.com/scientificreports/
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Figure 4. Exploration of multiple brain metastases reveal a phenotypical concordance of CD271 expression. 
(A) Schematic representation of plausible mechanisms of primary tumor (PM) or extracranial metastasis 
(EM) seeding to the brain suggesting either a multiple or single seeding of PM/EM or a combination of both 
leading to high phenotypic heterogeneity (left and right scheme) or phenotypic homogeneity (center scheme). 
Brain schemes were obtained from Servier (http://servier.com/Powerpoint-image-bank) as per Servier’s usage 
license (https://creativecommons.org/licenses/by/3.0/legalcode) and modified. (B) Immunohistochemistry 
of autopsied multiple brain metastases. In patient T1, all tumors (n = 3) located in the cerebellum and frontal 
cortex showed strong expression of CD271. (C) Areas indicating CD271+ cell migration /invasion into adjacent 
brain parenchyma of tumors described in (B), are shown. Insets show distant CD271+ cells. (D) Exploration of 
brain micrometastases located in the hippocampus and cortex of patient T3 for presence of CD271+ cells (black 
arrows).
www.nature.com/scientificreports/
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suggested previously44. In fact, a minority (~7% on average) of CD271+ cells in BM was in a non-proliferative 
state (Fig. 5B, lower panel). To further validate the inverse correlation of CD271 and MITF expression, we eval-
uated MITF expression levels and performed GSEA of CD271high and CD271low BM (GSE50493, GSE44660). 
Figure 5. CD271 high brain metastases lack expression of MITF. (A) Co-immunohistochemistry of a solitary BM 
of patient 1 (two different tumor areas) as well as multiple BM of patient T1 for CD271 (membrane, red) and 
MITF (nuclear, brown). (B) Upper and center panels: Staining of patient 1 BM for CD271 and Ki67. Lower panel, 
quantification of Ki67+, CD271+ and double positive cells of BM (n = 5) and EM (n = 6). (C) MITF expression 
levels (log2) of CD271high and CD271low BM of two independent studies (GSE50493, GSE44660) are shown. (D,E) 
GSEA of BM subsets analyzed in (C) and T20/02 cells with over expression of CD271 (T20/02CD271/NGFR) for 
enrichment of MITF-target genes as provided by TCGA43, compared to untransfected cells (Mock) is shown. In 
addition, GSEA revealed enrichment of melanoma aggressiveness-associated genes in A375 cells (CD271/NGFR 
vs. GFP) and BM. In (B) and (C) p-values were calculated by Wilcoxon rank-sum test.
www.nature.com/scientificreports/
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Indeed, we observed a higher expression of MITF in CD271low BM as well as an enrichment of MITF target 
genes43 (Fig. 5C-D). Furthermore, we found MITF target genes depleted in cells with forced expression of CD271 
(NGFR) as well as a more aggressive phenotype of CD271high A375 cells (A375CD271/NGFR) and BM (CD271high) by 
GSEA (Fig. 5E). In summary, these data suggest that the subset of CD271+ cells and brain metastases correlate 
with a MITFlow and more aggressive phenotype.
Discussion
Melanoma cell spreading to distant organs is still a challenge in melanoma therapy and associated with poor 
survival. Especially metastasis to the brain is frequently observed in melanoma patients and most likely presents a 
homing process of melanoma cells governed by specific cytokines or growth factors supplied by the brain tissue45. 
However, mechanisms determining the brain metastatic capacity of melanoma cells are still poorly understood. 
Recently, we demonstrated that expression of the nerve growth factor receptor CD271 determines melanoma cell 
properties and discriminates PM and MET by regulation of CD271-responsive genes27. Encouraged by the previ-
ous finding of increased expression of CD271 in BM as compared to EM9 we sought to evaluate as to whether the 
expression of CD271 and responsible genes indeed promote metastasis to the brain. Our initial analysis of brain 
and extracranial metastases showed a heterogeneous expression pattern of CD271 with a subset of CD271high BM. 
This was in line with publicly available expression data of melanoma brain metastases. Exploration of public data 
of BM of two independent studies demonstrated that expression of CD271 was sufficient to define a BM-subset 
exhibiting distinct features e.g. enrichment of CD271-responsible genes including those involved in DNA-repair, 
a stem-like phenotype or genesis of cell projections. Regarding the pronounced plasticity of melanoma cells32, 46, 
a high occurrence of CD271+ cells in melanoma BM may suggest that certain cellular phenotypes are possibly 
maintained in dependence of the prevailing microenvironment of tumors, epigenetic cues47 or stress e.g. induced 
by therapeutic interventions48 and may confer increased cell survival49. Comparison of both CD271high subsets 
revealed commonly regulated genes, associated with migration and metastasis. Since the number of BM of study 
GSE44660 was comparably low, we assumed this to be responsible for the low overlap of both studies. However, 
verification of individual genes common to both sets of CD271high BM showed a significant difference among 
CD271high and CD271low BM, suggesting CD271 to determine properties of a BM subset.
Remarkably, the BRAFV600E mutation intrinsically confers a high migratory phenotype to melanoma cells, 
which is blocked by the RAF-kinase inhibitor vemurafenib11. Nevertheless, patients under vemurafenib therapy 
show a higher incidence of brain metastases12 which is properly reasoned by the high brain metastatic poten-
tial of melanoma cells resistant to vemurafenib14. The latter cells show increased levels of CD271 which in turn 
is up-regulated via activation of the NFkB signaling pathway in BRAF-mutated melanoma cells13, most likely 
conferring increased migration. We observed a clear migratory phenotype of A375GFP cells in vitro and ex vivo 
(semi-in vivo) in organotypic brain slices. In fact, we observed CD271+ cells showing long-distance migration 
through the slice. We attempted to exemplary quantify the number of A375GFP cells showing a long-distance 
migration in the organotypic brain slice by counting of migrated cells. Nevertheless, an absolute quantification 
of migrating A375GFP cells is hampered by the lack of detailed insight into rates of proliferation and apoptosis 
within the slice.
CD271 expression - like other melanoma markers - underlies phenotype switching responsible for fluctu-
ations of CD271 expression44, 50. We demonstrated that A375 cells with stable over expression of CD271 are 
indeed capable of migration in brain slices. This may suggest that a CD271+ phenotype of brain metastases is not 
necessarily acquired following colonization but rather predetermined by migrating CD271+ cells. This is under-
pinned by our previous observation that over expression of CD271 enhanced migration of A375 cells in vitro27, 
suggesting an additional effect of CD271, potentially superior to the effects driven by oncogenic BRAF. However, 
mechanisms of CD271-dependent cell migration processes remain elusive and further studies are needed to fur-
ther explore this issue.
Exploration of CD271 and CD31 expression in solitary and multiple BM revealed that CD271+ cells are local-
ized around CD31+ vessels. Although we also observed CD271+ cells inside a blood vessel, this observation was 
extremely rare but may suggest a hematogenous dissemination of CD271+ cells into the brain as well as their 
migration along blood vessels51 (reviewed in ref. 42). Additionally, lymphatic spread of melanoma cells is of major 
prognostic relevance and the presence of CD271+ cells in lymph node metastases suggest a dual mechanism of 
dissemination.
Mechanisms involved in melanoma cell metastasis have been described previously, e.g. involving the cytokine 
receptor CXCR452, 53. However, this issue seems to be more complex and is determined by multiple factors, e.g. 
melanoma cell plasticity. We previously identified a CD271-dependend regulation of FGF13, a special type of 
non-secreted fibroblast growth factors, suggested to regulate neuronal microtubule assembly and stabilization33, 
migration, and chemo-resistance54. Together, this might suggest a CD271/FGF13 axis as yet another regulatory 
mechanism of melanoma cell migration. In addition, we found other factors known to be involved in cell migra-
tion, regulated in a CD271-dependent manner, e.g. CSPG434, 55 and HMGA235, strongly indicating that CD271 
expression is a prerequisite for proper melanoma cell migration. To further unravel a potential connection of 
CD271 and cell migration, we sought to identify genes responsible to HMGA2 and CD271. Since expression data 
of HMGA2 knock-down melanoma cells were not available, we utilized expression data of a breast cancer cell 
line (MDA-MB-231) with HMGA2 knock-down37 and identified HMGA2-responsible genes. Comparison of 
HMGA2- and CD271-responsible genes revealed a commonly regulated set of 130 genes, suggesting the indirect 
regulation of HMGA2 targets via CD271 and the potential existence of a HMGA2/CD271 network.
The proteoglycan CSPG4 is associated with cell migration or proliferation by regulation of small GTPases or 
fine-tuning of growth factor receptor signaling, respectively (reviewed in ref. 56). Due to the broad spectrum 
of signaling processes this receptor ties in, a reduced cell migration and cell-to ECM interaction seems to be a 
plausible consequence of the loss of CSPG4 expression. Since we observed co-expression of CSPG4 and CD271, a 
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concerted action of both receptors may regulate melanoma cell properties. However, CSPG4 expression in metas-
tases was not significantly higher as compared to primary melanoma. Although CD271 expression may facilitate 
melanoma cell migration, CD271 knock-down cells (BRAF wild type) retained a residual migratory capacity, sug-
gesting that additional, CD271-independent factors determine melanoma cell migration. Since FGF13, CSPG4 
and HMGA2 were not among the top up-regulated genes in the CD271high subset of brain metastases, these fac-
tors may not be involved in melanoma brain metastasis.
The exploration of solitary and multiple brain metastases clearly demonstrated that CD271+ cells colonize and 
disseminate within the brain and are supposedly involved in distant and intracerebral metastasis. We observed 
that CD271high BM showed a mutually exclusive expression of CD271 and MITF, hence a MITFlow phenotype. 
This was further supported by the finding that MITF-target genes were decreased in CD271high tumors reasoning 
the low level of c-MET which is transcriptionally regulated by MITF57. Hence, CD271high melanoma BM comprise 
a potentially individual subset with increased aggressiveness, increased DNA-repair capacity, stem-like properties 
or tendency to undergo EMT, and may respond differentially to therapeutic interventions. Moreover, the corre-
lation of CD271 expression and PI3K/AKT pathway activation adds another distinct feature of CD271high brain 
metastases.
In summary, our data suggest that CD271 expressing cells represent a population with brain metastatic 
capacity, capable of brain colonization and dissemination within the brain. Brain metastatic CD271+ cells fea-
ture increased DNA-repair, stem-like properties and low expression of MITF and MITF-targets, e.g. c-MET. 
Nevertheless, we observed CD271+ cells not exclusively in brain metastases but also in extracranial metastases of 
different sites. Hence, the question of how CD271+ cells prioritize the route of dissemination, remains. However, 
the high abundance of CD271+ cells in melanoma metastases suggests CD271 as a principal mediator of mela-
noma cell spreading. In fact, it has recently been shown in a mouse model system10 that targeting of CD271 may 
restrict or even prevent dissemination of primary melanoma. Besides CD271, other yet not fully understood 
factors like the interaction of melanoma cells with astrocytes or neuroinflammation58, seem to be prerequisites 
for the establishment of brain macrometastases.
Material and Methods
Patient cohorts. Archived (FFPE) matched pairs (n = 12) of extracranial (n = 13) and brain metastases 
(n = 12) including primary melanoma (n = 2) and unmatched extracranial (n = 1) and brain metastases (n = 7) 
were provided by the departments of pathology and neuropathology. Postmortem brains (n = 7) were taken 
48 hours after death with informed consent from patients, and fixed in 4% neutral-buffered formalin for 2 weeks. 
Then brains were sectioned and tissue samples were taken for neuropathological examinations. Tumor samples 
were sectioned (2–4 µm) following paraffin embedding and stained for CD271. In addition hematoxylin-eosin 
(H&E) staining of sections was performed for histological expertise. All experimental methods were performed 
in accordance with the approved guidelines. The present study was approved by the ethics committee of the 
Charité - Universitätsmedizin Berlin (EA2/175/16).
Cell culture. Patient-tumor derived cells (strain T20/02) as well as derivatives were cultured in Quantum 263 
tumor growth medium (Q236, Capricorn Scientific, Germany) supplemented with 1% penicillin/streptomycin 
(Invitrogen, USA). A375 cells (ATCC CRL-1619, USA) as well as genetically engineered derivatives (GFP, CD271/
NGFR) and MeWo cells (kind gift of Dr. Hermann Lage) were cultured in Leibovitz’s L-15 medium (Invitrogen) 
supplemented with 10% FBS, 1%, penicillin/streptomycin (Invitrogen), transferrin/fetuin, MEM-vitamines, insu-
lin, glucose and sodium bicarbonate. Medium was changed every 3 days as described previously27.
Organotypic slice cultures. Corticostriatal slice cultures were prepared from three-day-old mouse pups. 
Pups were sacrificed by instant decapitation. The brains were quickly removed and placed in a petri dish with 
ice cold Gibco Hanks’ Balanced Salt Solution. Both cerebral hemispheres were separated using a scalpel and 
sectioned coronally to 350 μm by a McIlwain tissue chopper (Mickle Laboratory, Cambridge, UK). The brain 
slices were separated under a dissection microscope (Leica S6 E) and placed on Millipore Millicell cell culture 
inserts (Millipore, Bedford, MA, USA) in a 6-well-plate with 1 ml culture medium (Gibco® RPMI + 10% heat 
inactivated FBS + 1% pen/strep). All experimental protocols were approved by the department of neuropathology 
of the Charité - Universitätsmedizin Berlin and all experimental methods were performed in accordance with the 
approved guidelines.
Intracranial invasion assay. GFP/NGFR-GFP cells were washed with 5 ml of PBS. PBS was aspirated and 2 
ml trypsin were added. The cells were incubated for 5 min, or until cells had detached, at 37 °C. 3 volumes of 10% 
FBS containing medium were added. The cells were centrifuged for 5 min at 1,100 rpm, medium was aspirated 
and cells were washed with PBS, a 50 μl aliquot of cells was saved for counting. After centrifugation, cells were 
re-suspended in fresh PBS to a concentration of 1 × 104 cells/μl and transferred into a sterile Eppendorf tube. A 
WPI’s UltraMicroPump III (UMP3, World Precision Instruments, Sarasota, FL) and a 1 µl Hamilton microsy-
ringe (Hamilton Company, Bonaduz, GR, Switzerland) were used to dispense 0.2 µl into the striatum. The injec-
tion was performed under a surgical microscope (Leica Wild M650) and GFP-positive tumor cells were visualized 
using fluorescent microscopy (Zeiss AxioObserver.Z1) every 24 hours. After 2 days the slices were fixed in 4% 
formaldehyde solution for 24 h at 4 °C.
Immunohistochemistry. Formaldehyde-fixed and paraffin-embedded tumors were sectioned to 2 µm, fol-
lowing de-waxing, peroxidase blocking and antigen-retrieval using EDTA buffer. Detection of CD271, CD31, 
Ki67, S100, vimentin, MITF, HMB45 and MART1/MLANA was performed with anti-CD271 (clone D4B3, 
XP, Cell signaling), anti-CD31 (clone JC/70A, Dako), anti-Ki67 (clone MIB1, Dako), anti-S100 (clone 15E2/
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E2, BioGenex), anti-vimentin (clone V9, Dako), anti-MITF (clones C5 + D5, Zytomed), anti-melanosom (clone 
HMB45, Dako) or anti-MART1 (clone A103, Dako) with an automated staining system (BenchMark Ultra, 
Ventana Medical Systems, USA). Histological staining was performed with hematoxylin/eosin (H&E, Merck). 
Immunohistochemical staining of two antigens was performed with the DakoCytomation kit (Dako).
Immunofluorescence and Confocal microscopy. Paraformaldehyde (PFA, 4%) fixed brain slices 
were mechanically removed, blocked (2% bovine serum albumin, BSA) and stained with either fluorescently 
(Phycoerythrin, PE) labeled or unlabeled anti-CD271 (Miltenyi, clone ME20.4–1.H4, mouse IgG1, or clone 
D4B3, XP, rabbit, 1:100, Cell signaling) and DAPI (4′,6-Diamidin-2-phenylindol, Sigma-Aldrich, 1:500), for 24 
hours at 4 °C. Images were captured using Zeiss Axiovert40CFL with accompanied Illuminator HPX120C and 
software AxioVision Rel. 4.8 (all Carl Zeiss AG, Germany). Confocal images were captured with Leica TCS SP5 
(Leica, Germany) using sequential scanning (z-stacking) at 200 Hz scan speed and 0.5 µm or 1 µm/stack. For 
immunofluorescence of tumors, sections were de-waxed followed by antigen-retrieval (citrate buffer pH = 6.0) 
for 20 min, washed in tris-buffered saline (TBS) and blocked in phosphate-buffered saline (PBS) with 2% bovine 
serum albumin (BSA) for 1h. Sections were incubated with blocking buffer and primary antibodies vimentin 
(mAB, clone V9, Invitrogen, Carlsbad, USA) and CD271 (clone D4B3, XP, Cell signaling) for 1 h at RT or over-
night at 4 °C. Sections were incubated for 1 h at RT with secondary antibodies AlexaFluor488 and 594 on second 
day, following washing of with PBS/Tween20 (0.1%). For cell-based immunofluorescence, cells were fixed directly 
on well plates, blocked with PBS/BSA and incubated with directly labeled antibodies CSPG4-FITC or CD271-PE 
(Miltenyi, Germany) or phalloidin-TRITC (Invitrogen) for 1h at RT.
BrdU labeling. Following incubation, cells were fixed with PFA (4%/PBS), permeabilized using triton-X100 
(0.1%/PBS) for 10 minutes and incubated with hydrochloric acid (2.5 M) for 30 minutes at RT. Following, cells 
were blocked with BSA and stained with anti-BrdU or Ki67 antibody (0.5 µg/ml final, BD Bioscience, Cat. 
No. 347580 or abcam, Cat. No. 66155) for 1 h at room temperature (RT). Secondary antibodies (anti-mouse 
AlexaFluor594 (BrdU) or 488 (Ki67), final concentration 2ug/ml) were added and incubated for 1 hour at RT.
Immunoblot. Total cell lysates were prepared in SDS lysis buffer (1% SDS, 10 mM Tris-HCl, 2 mM EDTA). 
10–25 µg of whole cell lysates were separated on 12% SDS-PAGE gels and transferred on a nitrocellulose mem-
brane by using the iBlot Dry Blotting System (Invitrogen). Membranes were blocked with Odyssey Blocking 
Buffer/PBS-Tween (0.1%), (1:1, LI-COR Biosciences, USA) for 1 h. Incubation with primary antibodies (p75NTR 
clone D4B3XP® recognizing the total CD271, p-ERK1/2, ERK1/2, p-AKT(S473), AKT, and β-tubulin, clone 9F3; 
all 1:1000; from Cell Signaling Technology, Germany) was done overnight at 4 °C. Incubation with secondary 
antibodies donkey anti-rabbit IgG or donkey anti-mouse both (diluted 1:10000; LI-COR Biosciences, USA) was 
done for 1 h at RT. Signals were detected with the Odyssey Infrared Imaging System (LI-COR Biosciences, USA).
RNA isolation and qRT-PCR. RNA isolation of frozen cell pellets was performed with the RNeasy Mini 
Kit (Qiagen, Germany), following the manufacturers protocol. Reverse transcription of 2.0 µg total RNA was 
performed with the SuperScript VILO cDNA synthesis kit (Invitrogen, Germany) and diluted to a final volume 
of 50 µl. qRT-PCR was carried out on a Step one plus (Applied Biosystems, Germany) for 40 cycles. Primers were 
designed using the PrimerQuest Tool (http://eu.idtdna.com/ primerquest/home/index) for 55–60 °C annealing 
temperature and product size of 100–250 bp (SI, Table S4). qPCR expression levels were calculated as relative 
expression by ΔΔCT, normalized to HPRT (hypoxanthine phosphoribosyltransferase 1).
Gene-set enrichment analysis (GSEA). GSEA was performed with appropriate software (GSEA version 
2.2.2) as well as signatures provided by the Broad institute (http://software.broadinstitute.org/gsea/index.jsp). 
Signatures specific for cell projections, focal adhesion, melanoma aggressiveness, DNA-repair, neural crest stem 
cells (NCSC) and EMT were received from the latest version of the Molecular Signatures Database v5.1 (MSigDB) 
of the Broad institute. Derivation of the CD271-responsive gene signature was performed as described previously27. 
Genes for signatures specifying MITF-targets and brain metastatic cells were derived from publications14, 43. 
Expression data of primary melanoma, extracranial metastases and brain metastases were obtained from GEO 
(Gene expression omnibus).
Data availability. The datasets analysed in the current study are available in the GEO database with accession 
numbers GSE7553 (skin cancer subtypes), GSE46517 (melanoma progression), GSE50493 (melanoma METs including 
brain METs, set 1), GSE44660 (brain METs set 2), GSE15605, GSE8401 (PM, MET), GSE52456 (shCD271, melanoma), 
GSE43741 (shHMGA2, breast cancer). CD271-responsive genes were extracted from data sets GSE78155: T20/02 
(CD271/NGFR; Mock) A375 (CD271/NGFR; GFP) as well as GSE52456 (shCD271, T20/02) as reported previously32.
Meta-analysis. Pre-processed data (normalized, batch-corrected) were imported to excel, log2 transformed and 
filtered for significance p ≤ 0.05, determined by a two-sided, two-sample ttest for unequal variance. Tables contain-
ing significant expression data (log2) were imported in R-studio (R Ver. 3.3.2) and tested for Gaussian distribution 
(p ≥ 0.05) by Shapiro testing. Tumor samples mostly did not show a Gaussian distribution and p-values were deter-
mined by a Wilcoxon rank-sum test. Box plots were generated using the box plot function of the ggplot2 package in 
combination with the beeswarm function. Heat maps were generated with heat map function of the gplot package. 
Brain and extracranial metastases with highest or lowest expression were designated as CD271high or CD271low, 
respectively. For identification of commonly regulated genes, lists containing either most up- or down-regulated 
genes were compared with R’s merge function. Duplicate gene symbols were removed by data filtering in excel. Due 
to the low sample number of brain metastases (n = 7) of study GSE44660 p-values were determined by ttest.
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